Firms continue their joint efforts to advance Nanobody-based biologics against the TNF-alpha receptor.
Ablynx extended its TNF-alpha partnership with Wyeth Pharmaceuticals for another year. The alliance is based on Ablynx’ Nanobody® technology.
Under the terms of the original agreement, the companies will collaborate to advance novel biologics through clinical development. Wyeth has the exclusive rights to the development and commercialization of the anti-TNF-alpha Nanobodies developed under this agreement.
Ablynx has already received an initial payment for research. Potential fees could total up to $212.5 million for development. Ablynx will also get royalties on product sales.
